Literature DB >> 24900471

Discovery and Structural Modification of 1-Phenyl-3-(1-phenylethyl)urea Derivatives as Inhibitors of Complement.

Mei Zhang1, Xiao-Ying Yang2, Wei Tang2, Tom W L Groeneveld3, Pei-Lan He2, Feng-Hua Zhu2, Jia Li4, Wei Lu5, Anna M Blom3, Jian-Ping Zuo2, Fa-Jun Nan4.   

Abstract

A series of 1-phenyl-3-(1-phenylethyl)urea derivatives were identified as novel and potent complement inhibitors through structural modification of the original compound from high-throughput screening. Various analogues (7 and 13-15) were synthesized and identified as complement inhibitors, with the introduction of a five- or six-carbon chain (7c, 7d, 7k, 7l, and 7o) greatly improving their activity. Optimized compound 7l has an excellent inhibition activity with IC50 values as low as 13 nM. We demonstrated that the compound 7l inhibited C9 deposition through the classical, the lectin, and the alternative pathways but had no influence on C3 and C4 depositions.

Entities:  

Keywords:  C9; complement inhibitors; high-throughput screening; structural modification

Year:  2012        PMID: 24900471      PMCID: PMC4025749          DOI: 10.1021/ml300005w

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  9 in total

Review 1.  Targeting complement in therapy.

Authors:  M Kirschfink
Journal:  Immunol Rev       Date:  2001-04       Impact factor: 12.988

Review 2.  The role of complement in inflammation and adaptive immunity.

Authors:  R Barrington; M Zhang; M Fischer; M C Carroll
Journal:  Immunol Rev       Date:  2001-04       Impact factor: 12.988

Review 3.  Synthetic small-molecule complement inhibitors.

Authors:  M Claire H Holland; Dimitrios Morikis; John D Lambris
Journal:  Curr Opin Investig Drugs       Date:  2004-11

Review 4.  Complement-targeted therapeutics.

Authors:  Daniel Ricklin; John D Lambris
Journal:  Nat Biotechnol       Date:  2007-11       Impact factor: 54.908

Review 5.  Therapeutic potential of complement modulation.

Authors:  Eric Wagner; Michael M Frank
Journal:  Nat Rev Drug Discov       Date:  2009-12-04       Impact factor: 84.694

6.  Diphenylphosphoryl azide. A new convenient reagent for a modified Curtus reaction and for the peptide synthesis.

Authors:  T Shioiri; K Ninomiya; S Yamada
Journal:  J Am Chem Soc       Date:  1972-08-23       Impact factor: 15.419

Review 7.  C1-Esterase inhibitor: an anti-inflammatory agent and its potential use in the treatment of diseases other than hereditary angioedema.

Authors:  C Caliezi; W A Wuillemin; S Zeerleder; M Redondo; B Eisele; C E Hack
Journal:  Pharmacol Rev       Date:  2000-03       Impact factor: 25.468

8.  The Arthus reaction in rodents: species-specific requirement of complement.

Authors:  A J Szalai; S B Digerness; A Agrawal; J F Kearney; R P Bucy; S Niwas; J M Kilpatrick; Y S Babu; J E Volanakis
Journal:  J Immunol       Date:  2000-01-01       Impact factor: 5.422

Review 9.  Recent developments in low molecular weight complement inhibitors.

Authors:  Hongchang Qu; Daniel Ricklin; John D Lambris
Journal:  Mol Immunol       Date:  2009-10-02       Impact factor: 4.407

  9 in total
  3 in total

Review 1.  The interaction between the complement system and hemostatic factors.

Authors:  Selin Oncul; Vahid Afshar-Kharghan
Journal:  Curr Opin Hematol       Date:  2020-09       Impact factor: 3.218

2.  Novel Trifluoromethylcoumarinyl Urea Derivatives: Synthesis, Characterization, Fluorescence, and Bioactivity.

Authors:  Lili Qiao; Shuanghong Hao
Journal:  Molecules       Date:  2018-03-07       Impact factor: 4.411

Review 3.  Targeting complement cascade: an alternative strategy for COVID-19.

Authors:  Sureshbabu Ram Kumar Pandian; Sankarganesh Arunachalam; Venkataraman Deepak; Selvaraj Kunjiappan; Krishnan Sundar
Journal:  3 Biotech       Date:  2020-10-19       Impact factor: 2.406

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.